Osteocalcin anticorps (AA 2-32)

N° du produit ABIN3030174

Cet anticorps anti-Osteocalcin est un anticorps Lapin Polyclonal détectant Osteocalcin dans IHC, WB et ELISA. Adapté pour Humain.

Aperçu rapide pour Osteocalcin anticorps (AA 2-32) (ABIN3030174)

Antigène: Osteocalcin (BGLAP)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Osteocalcin est non-conjugé

Application: Immunohistochemistry (IHC), Western Blotting (WB), ELISA

Détail du produit anti-Osteocalcin anticorps

Épitope: AA 2-32

Purification: Purified

Immunogène: A portion of amino acids 2-32 from the human protein was used as the immunogen for this Osteocalcin antibody.

Isotype: Ig Fraction

Information d'application

Indications d'application: Titration of the Osteocalcin antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the Osteocalcin antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Détails sur Osteocalcin

Antigène: Osteocalcin (BGLAP)

Autre désignation: Osteocalcin

Sujet: Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.

UniProt: P02818